Publications &
Presentations
In our pursuit of scientific advancement we are committed to sharing our acquired knowledge through actively publishing our data in peer-reviewed journals and academic conferences. We aim to provide a deeper understanding through extensive study and analysis on ileal bile acid transporter (IBAT) inhibition, for both the scientific and patient communities.
Research Updates
Featured Presentations & Publications
Maralixibat leads to significant reductions in bilirubin for patients with Progressive Familial Intrahepatic Cholestasis: Data from MARCH-PFIC
D’Antiga, et al. Oral Presentation, EASL 2023.
Long-term maintenance of response and improved liver health with maralixibat in patients with progressive familial intrahepatic cholestasis (PFIC): Data from the MARCH-ON study
Thompson, et al. Poster Presentation, EASL 2023.
Impact of maralixibat on cholestatic pruritus in adults aged 16 years and older with Alagille syndrome
Kamath, et al. Poster Presentation, EASL 2023.
Maralixibat leads to significant reductions in pruritus and improvements in sleep for children with Progressive Familial Intrahepatic Cholestasis: Data from MARCH-PFIC
Thompson, et al. Poster Presentation, EASL 2023.
Analysis of safety in maralixibat-treated participants with Progressive Familial Intrahepatic Cholestasis: Data from MARCH-PFIC
Miethke, et al. Poster Presentation, EASL 2023.
Latest Research Updates
Filter by topic
- SELECT
- Show all
- Alagille syndrome
- Biliary atresia
- Health economics and outcomes research
- IBAT inhibition
- LIVMARLI (maralixibat)
- Patient-reported outcomes validation
- Primary biliary cholangitis
- Primary sclerosing cholangitis
- Progressive familial intrahepatic cholestasis
- Volixibat
Until a relevant regulatory agency has approved a Mirum product for a specific disease or population, any scientific presentations regarding such disease or population are not to be considered instruction on the appropriate use of Mirum products or clinical candidates.
